Feasibility of conversion thoracoscopic esophagectomy after induction therapy for locally advanced unresectable esophageal squamous cell carcinoma

被引:6
|
作者
Kubo, Kentaro [1 ]
Kanematsu, Kyohei [1 ]
Kurita, Daisuke [1 ]
Ishiyama, Koshiro [1 ]
Oguma, Junya [1 ]
Itami, Jun [2 ]
Daiko, Hiroyuki [1 ]
机构
[1] Natl Canc Ctr, Dept Esophageal Surg, Tokyo, Japan
[2] Natl Canc Ctr, Dept Radiat Oncol, Tokyo, Japan
关键词
esophageal cancer; conversion surgery; thoracoscopic esophagectomy; MINIMALLY INVASIVE ESOPHAGECTOMY; PRONE POSITION; DOSE CHEMORADIOTHERAPY; SALVAGE ESOPHAGECTOMY; PHASE-II; CANCER; CISPLATIN; DOCETAXEL; SURGERY; 5-FLUOROURACIL;
D O I
10.1093/jjco/hyab085
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Recently, patients with cT4b esophageal cancer often require conversion surgery following induction therapy, for which the standard procedure is open esophagectomy. However, thoracoscopic esophagectomy, including thoracoscopic esophagectomy in the prone position, is increasingly used. We compared short-term outcomes of thoracoscopic esophagectomy and open esophagectomy in this setting. Methods: We retrospectively analyzed 14 patients who underwent thoracoscopic esophagectomy, and 10 who underwent open esophagectomy, for locally advanced unresectable esophageal cancer after induction therapy between March 2007 and July 2020. Results: The two groups did not significantly differ in patient background. Median total and thoracic surgical times were both significantly longer for open esophagectomy than for thoracoscopic esophagectomy. Median blood loss was also greater in the open esophagectomy group than in the thoracoscopic esophagectomy group. The thoracoscopic esophagectomy group also had significantly shorter median chest drain duration; and lower C-reactive protein levels on the second and third postoperative days. The two groups did not significantly differ in total complications or postoperative hospital stay. Conclusions: Thoracoscopic esophagectomy is as safe and feasible as open esophagectomy for conversion surgery after induction therapy for locally advanced unresectable esophageal squamous cell carcinoma.
引用
收藏
页码:1225 / 1231
页数:7
相关论文
共 50 条
  • [21] Open Versus Thoracoscopic Esophagectomy in Patients with Esophageal Squamous Cell Carcinoma
    Hsu, Po-Kuei
    Huang, Chien-Sheng
    Wu, Yu-Chung
    Chou, Teh-Ying
    Hsu, Wen-Hu
    WORLD JOURNAL OF SURGERY, 2014, 38 (02) : 402 - 409
  • [22] Comparison of robot-assisted esophagectomy and thoracoscopic esophagectomy in esophageal squamous cell carcinoma
    Park, Samina
    Hwang, Yoohwa
    Lee, Hyun Joo
    Park, In Kyu
    Kim, Young Tae
    Kang, Chang Hyun
    JOURNAL OF THORACIC DISEASE, 2016, 8 (10) : 2853 - 2861
  • [23] Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
    Wang, Xin
    Kang, Xiaozheng
    Zhang, Ruixiang
    Xue, Liyan
    Xu, Jiaqi
    Zhao, Xiaotian
    Ou, Qiuxiang
    Yu, Nuo
    Feng, Guojie
    Li, Jiao
    Zheng, Ziyu
    Chen, Xiankai
    Wang, Zhen
    Zheng, Qingfeng
    Li, Yong
    Qin, Jianjun
    Bi, Nan
    Li, Yin
    CLINICAL CANCER RESEARCH, 2024, 30 (22) : 5061 - 5072
  • [24] Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
    Shuwen Zheng
    Yumei Feng
    Chan Li
    Jie Zhang
    Ke Xie
    Oncology and Therapy, 2023, 11 : 185 - 198
  • [25] Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
    Zheng, Shuwen
    Feng, Yumei
    Li, Chan
    Zhang, Jie
    Xie, Ke
    ONCOLOGY AND THERAPY, 2023, 11 (02) : 185 - 198
  • [26] Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
    Cheng, Jiahan
    Guo, Minzhang
    Yang, Yushang
    Liu, Yilin
    Hu, Weipeng
    Shang, Qixin
    Li, Chuan
    Xia, Liang
    Wang, Yun
    Wang, Wenping
    Tian, Dong
    Yuan, Yong
    Hu, Yang
    Chen, Longqi
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [27] Efficacy and safety of definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma
    Habu, Takumi
    Bando, Hideaki
    Kumanishi, Ryosuke
    Ogata, Takatsugu
    Fujisawa, Takeshi
    Kumagai, Shogo
    Fujiwara, Hisashi
    Mishima, Saori
    Kotani, Daisuke
    Nakamura, Masaki
    Hojo, Hidehiro
    Yoda, Yusuke
    Koyama, Shohei
    Nishikawa, Hiroyoshi
    Yano, Tomonori
    Fujita, Takeo
    Kadowaki, Shigenori
    Muro, Kei
    Kinoshita, Takahiro
    Kojima, Takashi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [28] Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma
    Zhang, Wencheng
    Yan, Cihui
    Gao, Xuan
    Li, Xiaoxia
    Cao, Fuliang
    Zhao, Gang
    Zhao, Jingjing
    Er, Puchun
    Zhang, Tian
    Chen, Xi
    Wang, Yuwen
    Jiang, Yao
    Wang, Quanren
    Zhang, Baozhong
    Qian, Dong
    Wang, Jun
    Zhou, Dejun
    Ren, Xiubao
    Yu, Zhentao
    Zhao, Lujun
    Yuan, Zhiyong
    Wang, Ping
    Pang, Qingsong
    ONCOLOGIST, 2021, 26 (07): : E1110 - E1124
  • [29] Docetaxel, Cisplatin, and 5-FU Triplet Therapy as Conversion Therapy for Locoregionally Advanced Unresectable Esophageal Squamous Cell Carcinoma
    Wing-Lok Chan
    Cheuk-Wai Choi
    Ian Yu-Hong Wong
    Terence Hon-Ting Tsang
    Adrian Tin-Chung Lam
    Rosa Pui-Ying Tse
    K. K. Chan
    Claudia Wong
    Betty Tze-Ting Law
    Emina Edith Cheung
    Siu-Yin Chan
    Ka-On Lam
    Dora Kwong
    Simon Law
    Annals of Surgical Oncology, 2023, 30 : 861 - 870
  • [30] The safety and short-term efficacy of induction DCF plus nivolumab therapy in patients with unresectable locally advanced esophageal squamous cell carcinoma.
    Yamamoto, Shun
    Shiraishi, Kazuhiro
    Imazeki, Hiroshi
    Yoshinami, Yuri
    Ogura, Nozomu
    Itoyama, Mai
    Yokoyama, Kazuki
    Honma, Yoshitaka
    Kurita, Daisuke
    Ishiyama, Koshiro
    Oguma, Junya
    Kashihara, Tairo
    Hashimoto, Taiki
    Daiko, Hiroyuki
    Seto, Yasuyuki
    Kato, Ken
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 425 - 425